Display options
Cite
Esters P, Hackenberg C, Schulze H, et al. Biologika bei chronisch-entzündlichen Darmerkrankungen. [Biologics in inflammatory bowel diseases]. Internist (Berl). 2022;doi: 10.1007/s00108-021-01255-y.
Esters, P., Hackenberg, C., Schulze, H., & Dignass, A. U. (2022). Biologika bei chronisch-entzündlichen Darmerkrankungen. [Biologics in inflammatory bowel diseases]. Der Internist, . https://doi.org/10.1007/s00108-021-01255-y
Esters, Philip, et al. "Biologika bei chronisch-entzündlichen Darmerkrankungen." [Biologics in inflammatory bowel diseases]. Der Internist vol. (2022). doi: https://doi.org/10.1007/s00108-021-01255-y
Esters P, Hackenberg C, Schulze H, Dignass AU. Biologika bei chronisch-entzündlichen Darmerkrankungen. [Biologics in inflammatory bowel diseases]. Internist (Berl). 2022 Jan 17; doi: 10.1007/s00108-021-01255-y. Epub 2022 Jan 17. German. PMID: 35037947.
Copy Download .nbib Format: NLM
Share it on

Internist (Berl). 2022 Jan 17; doi: 10.1007/s00108-021-01255-y. Epub 2022 Jan 17.

[Biologics in inflammatory bowel diseases].

Der Internist

[Article in German]
Philip Esters, Christopher Hackenberg, Herrmann Schulze, Axel U Dignass

Affiliations

  1. Medizinische Klinik I, Agaplesion Markus Krankenhaus, Wilhelm-Epstein-Str. 4, 60431, Frankfurt am Main, Deutschland.
  2. Medizinische Klinik I, Agaplesion Markus Krankenhaus, Wilhelm-Epstein-Str. 4, 60431, Frankfurt am Main, Deutschland. [email protected].

PMID: 35037947 DOI: 10.1007/s00108-021-01255-y

Abstract

BACKGROUND: In addition to conventional anti-inflammatory treatment for chronic inflammatory bowel disease (IBD), there has been an evolution of new treatment options over the past 20 years. Already approved biologics provide multiple treatment alternatives but also make the treatment algorithms more complex. This development results in a substantial improvement in patient care. The ambitious treatment targets are associated with a higher quality of life and the reduction of long-term disability and morbidity.

OBJECTIVE: The aim of this article is to give an overview of how biologics can currently be implemented in IBD. In particular, the current clinical management is presented and an outlook on future treatment options with biologics for IBD is provided.

MATERIAL AND METHODS: A search was carried out in PubMed and ClinicalTrials.gov and the current German and European guidelines and expert recommendations were evaluated.

RESULTS: Since the late 1990s there have been a continuously increasing number of treatment options for IBD. All substances have proven safety and efficacy in large randomized clinical studies and enable increasingly more individualized treatment for patients with IBD. Biologics are currently the standard treatment of choice for moderate to severe inflammatory activity as well as for steroid-refractory or steroid-dependent courses of disease after failure of conventional treatment.

CONCLUSION: The diversity of IBD treatment offers increasing treatment options and thus improved patient care; however, as the number of new substances increases treatment becomes more complex. This article summarizes the current and future treatment options for IBD and their integration into current treatment algorithms.

© 2022. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.

Keywords: Antibodies, monoclonal; Biologics/drug monitoring; Biosimilar pharmaceuticals; Crohn disease; Ulcerative colitis

References

  1. Annunziato F, Cosmi L, Santarlasci V et al (2007) Phenotypic and functional features of human Th17 cells. J Exp Med 204(8):1849–1861. https://doi.org/10.1084/jem.20070663 - PubMed
  2. Fuss IJ, Neurath M, Boirivant M, Klein JS, de la Motte C, Strong SA et al (1996) Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn’s disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL‑5. J Immunol 157(3):1261–1270 - PubMed
  3. Teshima CW, Dieleman LA, Meddings JB (2012) Abnormal intestinal permeability in Crohn’s disease pathogenesis. Ann NY Acad Sci 1258:159–165. https://doi.org/10.1111/j.1749-6632.2012.06612.x - PubMed
  4. Nathan C, Ding A (2010) Nonresolving inflammation. Cell 140(6):871–882 - PubMed
  5. Targan SR, Hanauer SB, van Deventer SJ et al (1997) A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N Engl J Med 337(15):1029–1035 - PubMed
  6. Hanauer SB, Feagan BG, Lichtenstein GR et al (2002) Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 359(9317):1541–1549 - PubMed
  7. Järnerot G, Hertervig E, Friis-Liby I et al (2005) Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 128(7):1805–1811 - PubMed
  8. Present DH, Rutgeerts P, Targan S et al (1999) Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med 340(18):1398–1405 - PubMed
  9. Probert CSJ, Hearing SD, Schreiber S et al (2003) Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut 52(7):998–1002 - PubMed
  10. Ricart E, Sandborn WJ (1999) Infliximab for the treatment of fistulas in patients with Crohn’s disease. Gastroenterology 117(5):1247–1248 - PubMed
  11. Rutgeerts P, Sandborn WJ, Feagan BG et al (2005) Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353(23):2462–2476 - PubMed
  12. Colombel J‑F, Sandborn WJ, Rutgeerts P et al (2007) Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology 132(1):52–65. https://doi.org/10.1053/j.gastro.2006.11.041 - PubMed
  13. Sandborn WJ, Feagan BG, Rutgeerts P et al (2013) Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med 369(8):711–721 - PubMed
  14. Feagan BG, Rutgeerts P, Sands BE et al (2013) Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 369(8):699–710 - PubMed
  15. Sandborn WJ, Gasink C, Gao L‑L et al (2012) Ustekinumab induction and maintenance therapy in refractory Crohn’s disease. N Engl J Med 367(16):1519–1528 - PubMed
  16. Feagan BG, Sandborn WJ, Gasink C et al (2016) Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med 375(20):1946–1960 - PubMed
  17. Sands BE, Sandborn WJ, Panaccione R et al (2019) Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 381(13):1201–1214 - PubMed
  18. Hanžel J, D’Haens GR (2020) Anti-interleukin-23 agents for the treatment of ulcerative colitis. Expert Opin Biol Ther 20(4):399–406. https://doi.org/10.1080/14712598.2020.1697227 - PubMed
  19. Macaluso FS, Orlando A, Cottone M (2019) Anti-interleukin-12 and anti-interleukin-23 agents in Crohn’s disease. Expert Opin Biol Ther 19(2):89–98. https://doi.org/10.1080/14712598.2019.1561850 - PubMed
  20. Joensuu JT, Huoponen S, Aaltonen KJ et al (2015) The cost-effectiveness of biologics for the treatment of rheumatoid arthritis: a systematic review. PLoS ONE 10(3):e119683. https://doi.org/10.1371/journal.pone.0119683 - PubMed
  21. Martelli L, Peyrin-Biroulet L (2019) Efficacy, safety and immunogenicity of biosimilars in inflammatory bowel diseases: a systematic review. Curr Med Chem 26(2):270–279 - PubMed
  22. Goll GL, Jørgensen KK, Sexton J et al (2019) Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trial. J Intern Med 285(6):653–669. https://doi.org/10.1111/joim.12880 - PubMed
  23. Reddy KR, Beavers KL, Hammond SP et al (2015) American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 148(1):215–219. https://doi.org/10.1053/j.gastro.2014.10.039 (quiz e16–e17) - PubMed
  24. Sands BE, Peyrin-Biroulet L, Loftus EV et al (2019) Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis. N Engl J Med 381(13):1215–1226 - PubMed
  25. Sands BE, Irving PM, Hoops T et al (2021) 775d Ustekinumab versus adalimumab for induction and maintenance therapy in moderate-to-severe Crohn’s disease: the SEAVUE study. Gastroenterology 161(2):e30–e31 - PubMed
  26. Gomollón F, Dignass A, Annese V et al (2017) 3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: part 1: diagnosis and medical management. J Crohns Colitis 11(1):3–25. https://doi.org/10.1093/ecco-jcc/jjw168 - PubMed
  27. Ponsioen CY, de Groof EJ, Eshuis EJ et al (2017) Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn’s disease: a randomised controlled, open-label, multicentre trial. Lancet Gastroenterol Hepatol 2(11):785–792 - PubMed
  28. Bouhnik Y, Carbonnel F, Laharie D et al (2018) Efficacy of adalimumab in patients with Crohn’s disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study. Gut 67(1):53–60. https://doi.org/10.1136/gutjnl-2016-312581 - PubMed
  29. Kopylov U, Ron Y, Avni-Biron I et al (2017) Efficacy and safety of vedolizumab for induction of remission in inflammatory bowel disease—the Israeli real-world experience. Inflamm Bowel Dis 23(3):404–408 - PubMed
  30. Steenholdt C (2013) Use of infliximab and anti-infliximab antibody measurements to evaluate and optimize efficacy and safety of infliximab maintenance therapy in Crohn’s disease. Dan Med J 60(4):B4616 - PubMed
  31. Laharie D, Bourreille A, Branche J et al (2012) Ciclosporin vs. infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet 380:1909–1915 - PubMed

Publication Types